Biofrontera Inc. announced the appointment of Heikki Lanckriet, Ph.D. to its board of directors. Dr. Lanckriet brings to the company more than 20 years of commercial and scientific experience in the life sciences industry, along with proven success in developing high-growth technology companies. Dr. Lanckriet was nominated to the company's board of directors by Biofrontera AG under the terms of the April 2023 settlement agreement between the two companies previously disclosed in the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 17, 2023.

Dr. Lanckriet currently serves as a member of Biofrontera AG's Supervisory Board. Dr. Lanckriet currently serves as chief executive officer and chief scientific officer of 4basebio PLC, UK. In 2020 Heikki led the sale of Expedeon's proteomics and immunology business to Abcam PLC.

Earlier, Dr. Lanckriet was Founder and Chief Scientific Officer of Novexin, later transitioning to Chief Operating Officer. Dr. Lanckriet also held roles as Chief Executive Officer and Chief Scientific Officer at 2invest AG and Sygnis AG. Dr. Lanckriet holds a Ph.D. in Chemical Engineering from the University of Cambridge in the U.K. and a M.Eng.

in Chemical Engineering from the University of Ghent in Belgium. He has authored several scientific papers that have been published in peer-reviewed medical and scientific journals, and is a named inventor on a multitude of patents.